A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

Blood

Volumn 109, Issue 6, 2007, Pages 2571-2578

  Perrine, Susan P ^a   Hermine, Olivier ^b   Small, Trudy ^c   Suarez, Felipe ^b   O'Reilly, Richard ^c   Boulad, Farid ^c   Fingeroth, Joyce ^f   Askin, Melissa ^a   Levy, Arthur ^e   Mentzer, Steven J ^d   Di Nicola, Massimo ^h   Gianni, Alessandro M ^h   Klein, Christoph ^g   Horwitz, Steven ^c   Faller, Douglas V ^a,i  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ K 701   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ARGININE BUTYRATE; ARGININE DERIVATIVE; BUTYRIC ACID DERIVATIVE; GANCICLOVIR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUDITORY HALLUCINATION; B LYMPHOCYTE; BACKACHE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DISORIENTATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL INFECTION; HALLUCINATION; HEADACHE; HEPATITIS; HEPATOMEGALY; HUMAN; HYPESTHESIA; HYPOKALEMIA; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; INTESTINE PERFORATION; LATENT VIRUS INFECTION; LETHARGY; LUNG GRAFT REJECTION; LUNG HEMORRHAGE; LYMPHOMA; LYMPHOMA CELL; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA AND VOMITING; PANCREATITIS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RESTLESSNESS; SEPSIS; SIDE EFFECT; SINUS PAIN; SOMNOLENCE; STANDING; STAPHYLOCOCCUS INFECTION; STUPOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VIRUS INFECTION; VISION;

EID: 33947275876     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-024703     Document Type: Article

References (99)

1. Kawa K. Epstein-Barr virus-associated disease in humans. Int J Hematol. 2000;71:108-117.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Virology. Philadelphia, PA: Lippincott-Raven; 1996:2397-2446.
3. Maia DM, Peace-Brewer AL. Chronic, active Epstein-Barr virus infection. Curr Opin Hematol. 2000;7:59-63.
4. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34:27-53.
5. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A. 1968;58:94-101.
6. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218-223.
7. Henle W, Henle G. Epstein-Barr virus and human malignancies. Adv Viral Oncol. 1985;5:201-238.
8. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970;228:1056-1058.
9. Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med. 1985;313:1564.
10. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus-induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg. 1983;198:356-369.
11. Briz M, Fores R, Regidor C, et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol. 1997;98:485-487.
12. Shibata D, Weiss LM, Hernandez AM. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;91:2101-2109.
13. Jones JF, Shurin S, Abramowsky C. et al. T-cell lymphomas containing Epstein-Barr virus DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733-741.
14. Su I-J, Hsieh H-C, Lin K-H, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 1991;77:799-808.
15. Meijer CJLM, Jiwa NM, Dukers DF, et al. Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol. 1996;7:191-196.
16. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr virus in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502.
17. Niedobitek G. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Ann Oncol. 1996;7:S11-S17.
18. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375-382.
19. Pagano JS. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians. 1999;111:573-580.
20. Brooks LA, Crook T, Crawford DH. Epstein-Barr virus and lymphomas. Cancer Surv. 1999;33:99-123.
21. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med. 1995;332:12-18.
22. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med. 1995;332:19-25.
23. Leoncini L, Vindigni C, Megha T, et al. Epstein-Barr virus and gastric cancer: data and unanswered questions. Int J Cancer. 1993;53:898-901.
24. Osato T, Imai S. Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol. 1996;7:175-182.
25. Chu JS, Chen CC, Chang KJ. In situ detection of Epstein-Barr virus in breast cancer. Cancer Lett. 1998;124:53-57.
26. Bonnet M, Guinebretiere JM, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst. 1999;91:1376-1381.
27. Magrath I, Bhatia K. Breast cancer: a new Epstein-Barr virus-associated disease? J Natl Cancer Inst. 1999;91:1349-1350.
28. Speck P, Longnecker R. Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact. J Natl Cancer Inst. 2000;92:1849-1851.
29. Kleer CG, Tseng MD, Gutsch DE, et al. Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts. Modern Pathol. 2002;15:759-764.
30. Littler E, Zeuthen J, McBride AA, et al. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J. 1986;5:1959-1966.
31. Stinchcobe T, Clough W. Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines. Biochemistry. 1985;24:2021-2033.
32. Lin J-C, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-Dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus. J Virol. 1984;50:50-55.
33. Littler E, Arrand JR. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J Virol. 1988;62:3892-3895.
34. Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 1998;42:2923-2931.
35. Gershburg E, Marschall M, Hong K, Pagano JS. Expression and localization of the Epstein-Barr virus-encoded protein kinase. J Virol. 2004;78:12140-12146.
36. Newman C, Polk BF. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). Annal Int Med. 1987;107:348-350.
37. Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA. 1988;259:384-388.
38. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for EBV-associated malignancies. Curr Opin Oncol. 2001;13:360-367.
39. Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus (EBV)-associated lymphoma. Blood Cells Mol Dis. 1998;24:114-123.
40. Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological reactivation of viral target genes with arginine butyrate. Transplant Infec Dis. 2001;3:177-185.
41. Park JH, Faller DV. Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology. 2002;303:345-363.
42. Anisimova E, Rachova K, Roubal J, Vonka V. Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol. 1984;81:223-237.
43. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemia cell. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer. 1983;51:9-14.
44. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol. 1987;23:1283-1289.
45. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93:1790-1797.
46. Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and β-thalassemia. Curr Opin Hemat. 1995;2:109-117.
47. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81-86.
48. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin gene expression in the β-globin disorders. N Engl J Med. 1993;328:81-86.
49. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002;100:4640-4648.
50. Ghez D, Damotte D, Perrine SP, et al. Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma. Clin Lymphoma Myeloma. 2006;6:417-419.
51. de Bruin PC, Jiwa M, Oudejans JJ. et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood. 1994;83:1612-1618.
52. Ho FCS, Srivastava G, Loke S, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas. Hematol Oncol. 1990;8:271-281.
53. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128-130.
54. Kanavaros P, Lescs M-C, Briere J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 1993;81:2688-2695.
55. de Bruin PC, Jiwa NM, Van der Valk P, et al. Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: relation between latent membrane protein I positively and clinical course. Histopathology. 1993;23:509-518.
56. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175-184.
57. Hahn JS, Lee ST, Min YH, et al. Therapeutic outcome of Epstein-Barr virus positive T/NK cell lymphoma in the upper aerodigestive tract. Yonsei Med J. 2002;43:175-182.
58. Johansson B, Klein G, Henle W, Henle G. Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia, 1: Hodgkin's disease. Int J Cancer. 1970;5:450-462.
59. Weiss LM, Strickler JG, Wamke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129:86-91.
60. Wu T-C, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990;46:801-804.
61. Armstrong AA, Weiss LM, Gallagher A, et al. Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease. Leukemia. 1992;6:869-874.
62. Gross TG, Steinbuch M, Defor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation. Risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251-258.
63. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
64. Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol. 1999;26:21-25.
65. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol. 1997;14:2-7.
66. Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:108-118.
67. Nagafuji K, Eto T, Hayashi S, et al. Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant. 1998;21:1155-1158.
68. Imashuka S, Goto T, Matsumura T, et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant. 1997;20:337-340.
69. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96:4055-4063.
70. Horwitz SM, Horning SJ. Rituximab in stem cell transplantation for aggressive lymphoma. Curr Hematol Rep. 2004;3:227-229.
71. Milpied N, Vasseur B, Parquet, N et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11:S113-S116.
72. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci U SA. 1983;80:2767-2770.
73. Bacon TH, Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrob Agents Chemother. 1995;39:1599-1602.
74. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980;34:560-568.
75. Zutter MM, Martin PJ, Sale GE, Shulman HM. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520-529.
76. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med. 1989;86:241-244.
77. Delone P, Corkill J, Jordan M, et al. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplant Proc. 1995;27:58-59.
78. Charollais RH, Buguet C, Mester J. Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31. J Cell Phys. 1990;145:46-52.
79. Saito H, Morizane T, Watanabe T, et al. Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T. Int J Cancer. 1991;48:291-296.
80. Perrine SP, Miller BA, Greene MF, et al. Butyric acid analogues augment gamma globin gene expression in neonatal erythroid progenitors. Biochem Biophys Res Commun. 1987;148:694-700.
81. Gum JR, Kam WK, Byrd JC, et al. Effects of sodium butyrate on human colonic adenocarcinoma cells. Induction of placental-like alkaline phosphatase. J Biol Chem. 1987;262:1092-1097.
82. He R-Y, Breitman TR. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL-60 cells while synergistically inducing granulocytoid differentiation. Eur J Haematol. 1991;46:93-100.
83. Kim YS, Tsao D, Sidoliqui B, et al. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer. 1980;45:1185-1192.
84. Saini K, Steele G, Thomas P. Induction of carcinoembryonic-antigen-gene expression in human colorectal carcinoma by sodium butyrate. Biochem J. 1990;272:541-544.
85. Boffa LC, Vidali G, Mann RS, Allfrey VG. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem. 1978;253:3364-3366.
86. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 1977;268:462-464.
87. Planchon P, Raux H, Magnien V, et al. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells. Int J Cancer. 1991;48:443-449.
88. Wintersberger E, Mudrak I. Sodium butyrate inhibits the synthesis of the transformation related protein p53 in 3T6 mouse fibroblasts. FEBS Lett. 1984;166:326-330.
89. Bruce JH, Ramirez A, Lin L, Agarwal RP. Effects of cyclic AMP and butyrate on cell cycle, DNA, RNA, and purine synthesis of cultured astrocytes. Neurochem Res. 1992;17:315-320.
90. Vaziri C, Stice L, Faller DV. Butyrate-induced G(1) arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 1998;9:465-474.
91. Kip1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol. 2005;202:87-99.
92. Sanders DA, Tansan ST, Arthur V, et al. Phase I clinical trial of arginine butyrate in patients with refractory neoplasms [abstract]. Proc ASCO. 1995;14:476.
93. Roychowdhury S, Baiocchi RA, Vourganti S, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. 2004;96:1447-1457.
94. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636-4643.
95. Carducci MA, Gilbert J, Bowling MK, et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001;7:3047-3055.
96. Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 1995;75:2932-2938.
97. Edelman MJ, Bauer K, Khanwani S, et al. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmacol. 2003;51:439-444.
98. Cytovene. Physicians' Desk Reference. Florence, KY: Thompson Healthcare; 2006:2763-2769.
99. Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis. 2007;38:57-65.